Business Context and Reporting Period
This Form 8-K is a current report filed by Mast Therapeutics, Inc. (not Savara Inc.) on March 14, 2016, regarding events occurring on March 9 and March 10, 2016. The filing addresses corporate governance changes involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
- Director Resignation: Lewis Shuster resigned from the Board of Directors and all committees effective March 10, 2016.
- Reason for Departure: The resignation was to focus on new and existing opportunities and was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Committee Appointments: On March 10, 2016, the Board appointed David Ramsay to the Nominating and Governance Committee and Matthew Pauls to the Audit Committee to fill the vacancies.
- Committee Composition:
- Nominating and Governance Committee: Howard Dittrich (Chair), Matthew Pauls, and David Ramsay.
- Audit Committee: David Ramsay (Chair), Peter Greenleaf, and Matthew Pauls.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Confirm the identity of the registrant as Mast Therapeutics, Inc., noting the discrepancy with the requested company name (Savara Inc.).
- Verify the effective date of Lewis Shuster's resignation (March 10, 2016).
- Confirm the new leadership structure of the Audit and Nominating and Governance Committees.
- Review subsequent filings to determine if the resignation impacts the company's strategic direction or board stability.